Skip to main content
Top
Published in: Annals of Hematology 1/2021

Open Access 01-01-2021 | Thrombocytopenia | Original Article

Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study

Authors: Loes L. Cornelissen, Aukje L. Kreuger, Camila Caram-Deelder, Rutger A. Middelburg, Jean Louis H. Kerkhoffs, Peter A. von dem Borne, Erik A. M. Beckers, Karen M. K. de Vooght, Jürgen Kuball, J. J. Zwaginga, Johanna G. van der Bom

Published in: Annals of Hematology | Issue 1/2021

Login to get access

Abstract

We designed a study to describe the incidence of intracranial hemorrhage according to severity and duration of thrombocytopenia and to quantify the associations of platelet transfusions with intracranial hemorrhage in patients with acute leukemia. In this case-control study nested in a cohort of 859 leukemia patients, cases (n = 17) were patients diagnosed with intracranial hemorrhage who were matched with control patients (n = 55). We documented platelet counts and transfusions for seven days before the intracranial hemorrhage in cases and in a “matched” week for control patients. Three measures of platelet count exposure were assessed in four potentially important time periods before hemorrhage. Among these leukemia patients, we observed the cumulative incidence of intracranial hemorrhage of 3.5%. Low platelet counts were, especially in the three to seven days preceding intracranial hemorrhage, associated with the incidence of intracranial hemorrhage, although with wide confidence intervals. Platelet transfusions during the week preceding the hemorrhage were associated with higher incidences of intracranial hemorrhage; rate ratios (95% confidence interval) for one or two platelet transfusions and for more than two transfusions compared with none were 4.04 (0.73 to 22.27) and 8.91 (1.53 to 51.73) respectively. Thus, among acute leukemia patients, the risk of intracranial hemorrhage was higher among patients with low platelet counts and after receiving more platelet transfusions. Especially, the latter is likely due to clinical factors leading to increased transfusion needs.
Appendix
Available only for authorised users
Literature
4.
go back to reference Groch SN, Sayre GP, Heck FJ (1960) Cerebral hemorrhage in leukemia. Arch Neurol 2:439–451CrossRef Groch SN, Sayre GP, Heck FJ (1960) Cerebral hemorrhage in leukemia. Arch Neurol 2:439–451CrossRef
12.
go back to reference Zhang XH, Wang QM, Chen H, Chen YH, Han W, Wang FR, Wang JZ, Zhang YY, Mo XD, Chen Y, Wang Y, Chang YJ, Xu LP, Liu KY, Huang XJ (2016) Clinical characteristics and risk factors of intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Ann Hematol 95(10):1637–1643. https://doi.org/10.1007/s00277-016-2767-yCrossRefPubMed Zhang XH, Wang QM, Chen H, Chen YH, Han W, Wang FR, Wang JZ, Zhang YY, Mo XD, Chen Y, Wang Y, Chang YJ, Xu LP, Liu KY, Huang XJ (2016) Clinical characteristics and risk factors of intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Ann Hematol 95(10):1637–1643. https://​doi.​org/​10.​1007/​s00277-016-2767-yCrossRefPubMed
16.
go back to reference Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dolken G, Klenner A, Hanel M, Herbst R, Junghanss C, Ehninger G, Study Alliance L (2012) Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 380(9850):1309–1316. https://doi.org/10.1016/S0140-6736(12)60689-8CrossRefPubMed Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dolken G, Klenner A, Hanel M, Herbst R, Junghanss C, Ehninger G, Study Alliance L (2012) Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 380(9850):1309–1316. https://​doi.​org/​10.​1016/​S0140-6736(12)60689-8CrossRefPubMed
20.
go back to reference Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth AT, Djulbegovic B, Panel APTG (2015) Platelet transfusion: a systematic review of the clinical evidence. Transfusion 55 (5):1116–1127; quiz 1115. https://doi.org/10.1111/trf.12943 Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth AT, Djulbegovic B, Panel APTG (2015) Platelet transfusion: a systematic review of the clinical evidence. Transfusion 55 (5):1116–1127; quiz 1115. https://​doi.​org/​10.​1111/​trf.​12943
23.
25.
go back to reference Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214CrossRef Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214CrossRef
26.
go back to reference Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, Norfolk D, Copplestone A, Smith N, Kerr P, Jones G, Raj K, Westerman DA, Szer J, Jackson N, Bardy PG, Plews D, Lyons S, Bielby L, Wood EM, Murphy MF, Investigators T (2013) A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 368(19):1771–1780. https://doi.org/10.1056/NEJMoa1212772CrossRefPubMed Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, Norfolk D, Copplestone A, Smith N, Kerr P, Jones G, Raj K, Westerman DA, Szer J, Jackson N, Bardy PG, Plews D, Lyons S, Bielby L, Wood EM, Murphy MF, Investigators T (2013) A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 368(19):1771–1780. https://​doi.​org/​10.​1056/​NEJMoa1212772CrossRefPubMed
27.
28.
go back to reference Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, Investigators P (2016) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387(10038):2605–2613. https://doi.org/10.1016/S0140-6736(16)30392-0CrossRefPubMed Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, Investigators P (2016) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387(10038):2605–2613. https://​doi.​org/​10.​1016/​S0140-6736(16)30392-0CrossRefPubMed
29.
go back to reference Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D’Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T, PlaNe TMC (2019) Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med 380(3):242–251. https://doi.org/10.1056/NEJMoa1807320CrossRefPubMed Curley A, Stanworth SJ, Willoughby K, Fustolo-Gunnink SF, Venkatesh V, Hudson C, Deary A, Hodge R, Hopkins V, Lopez Santamaria B, Mora A, Llewelyn C, D’Amore A, Khan R, Onland W, Lopriore E, Fijnvandraat K, New H, Clarke P, Watts T, PlaNe TMC (2019) Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med 380(3):242–251. https://​doi.​org/​10.​1056/​NEJMoa1807320CrossRefPubMed
32.
go back to reference Miettinen O (1976) Estimability and estimation in case-referent studies. Am J Epidemiol 103(2):226–235CrossRef Miettinen O (1976) Estimability and estimation in case-referent studies. Am J Epidemiol 103(2):226–235CrossRef
35.
go back to reference Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM (2006) The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 91(11):1530–1537PubMed Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM (2006) The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 91(11):1530–1537PubMed
36.
go back to reference Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S (2002) Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16(1):34–45CrossRef Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S (2002) Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16(1):34–45CrossRef
38.
go back to reference Keller TT, Mairuhu AT, de Kruif MD, Klein SK, Gerdes VE, ten Cate H, Brandjes DP, Levi M, van Gorp EC (2003) Infections and endothelial cells. Cardiovasc Res 60(1):40–48CrossRef Keller TT, Mairuhu AT, de Kruif MD, Klein SK, Gerdes VE, ten Cate H, Brandjes DP, Levi M, van Gorp EC (2003) Infections and endothelial cells. Cardiovasc Res 60(1):40–48CrossRef
Metadata
Title
Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study
Authors
Loes L. Cornelissen
Aukje L. Kreuger
Camila Caram-Deelder
Rutger A. Middelburg
Jean Louis H. Kerkhoffs
Peter A. von dem Borne
Erik A. M. Beckers
Karen M. K. de Vooght
Jürgen Kuball
J. J. Zwaginga
Johanna G. van der Bom
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 1/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04298-7

Other articles of this Issue 1/2021

Annals of Hematology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.